Below are the most recent publications written about "Carcinoma, Neuroendocrine" by people in Profiles.
-
Cimic A, Vranic S, Arguello D, Contreras E, Gatalica Z, Swensen J. Molecular Profiling Reveals Limited Targetable Biomarkers in Neuroendocrine Carcinoma of the Cervix. Appl Immunohistochem Mol Morphol. 2021 04 01; 29(4):299-304.
-
Balakrishna P, George S, Hatoum H, Mukherjee S. Serotonin Pathway in Cancer. Int J Mol Sci. 2021 Jan 28; 22(3).
-
Vuong HG, Ho ATN, Tran TTK, Capdevila J, Benekli M, Nakazawa T, Katoh R, Kondo T. Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: A systematic review and meta-analysis. Head Neck. 2019 08; 41(8):2823-2829.
-
Vranic S, Palazzo J, Sanati S, Florento E, Contreras E, Xiu J, Swensen J, Gatalica Z. Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast. Clin Breast Cancer. 2019 04; 19(2):131-136.
-
Vuong HG, Odate T, Ngo HTT, Pham TQ, Tran TTK, Mochizuki K, Nakazawa T, Katoh R, Kondo T. Clinical significance of RET and RAS mutations in sporadic medullary thyroid carcinoma: a meta-analysis. Endocr Relat Cancer. 2018 06; 25(6):633-641.
-
Vanden Borre P, Schrock AB, Anderson PM, Morris JC, Heilmann AM, Holmes O, Wang K, Johnson A, Waguespack SG, Ou SI, Khan S, Fung KM, Stephens PJ, Erlich RL, Miller VA, Ross JS, Ali SM. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions. Oncologist. 2017 03; 22(3):255-263.
-
Adhikari LJ, Sciallis AP, Reynolds J, Jenkins S, Smith C, Stan MN, Nassar A. Clinicopathologic predictors of thyroid bed recurrence of differentiated thyroid cancer using ultrasound-guided fine-needle aspiration biopsies. Thyroid. 2013 Aug; 23(8):982-8.
-
Singhi AD, Chu LC, Tatsas AD, Shi C, Ellison TA, Fishman EK, Kawamoto S, Schulick RD, Wolfgang CL, Hruban RH, Edil BH. Cystic pancreatic neuroendocrine tumors: a clinicopathologic study. Am J Surg Pathol. 2012 Nov; 36(11):1666-73.
-
de Wilde RF, Heaphy CM, Maitra A, Meeker AK, Edil BH, Wolfgang CL, Ellison TA, Schulick RD, Molenaar IQ, Valk GD, Vriens MR, Borel Rinkes IH, Offerhaus GJ, Hruban RH, Matsukuma KE. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors. Mod Pathol. 2012 Jul; 25(7):1033-9.
-
Engles CD, Slobodov G, Buethe DD, Lightfoot S, Culkin DJ. Primary mixed neuroendocrine carcinoma of the bladder with large cell component: a case report and review of the literature. Int Urol Nephrol. 2012 Aug; 44(4):1021-5.